Zhang Yingjun, Zhang Ge, Wang Yuefang, Ye Lei, Peng Luyun, Shi Rui, Guo Siqi, He Jiajing, Yang Hao, Dai Qingkai
Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.
Front Oncol. 2024 Feb 21;14:1324859. doi: 10.3389/fonc.2024.1324859. eCollection 2024.
Acute lymphocytic leukemia is a hematological malignancy that primarily affects children. Long-term chemotherapy is effective, but always causes different toxic side effects. With the application of a chemotherapy-free treatment strategy, we intend to demonstrate the most recent results of using one type of epigenetic drug, histone deacetylase inhibitors, in ALL and to provide preclinical evidence for further clinical trials. In this review, we found that panobinostat (LBH589) showed positive outcomes as a monotherapy, whereas vorinostat (SAHA) was a better choice for combinatorial use. Preclinical research has identified chidamide as a potential agent for investigation in more clinical trials in the future. In conclusion, histone deacetylase inhibitors play a significant role in the chemotherapy-free landscape in cancer treatment, particularly in acute lymphocytic leukemia.
急性淋巴细胞白血病是一种主要影响儿童的血液系统恶性肿瘤。长期化疗有效，但总会引起不同的毒副作用。随着无化疗治疗策略的应用，我们旨在展示使用一种表观遗传药物——组蛋白去乙酰化酶抑制剂治疗急性淋巴细胞白血病的最新结果，并为进一步的临床试验提供临床前证据。在本综述中，我们发现帕比司他（LBH589）作为单一疗法显示出积极效果，而伏立诺他（SAHA）更适合联合使用。临床前研究已确定西达本胺是未来更多临床试验中值得研究的潜在药物。总之，组蛋白去乙酰化酶抑制剂在癌症治疗的无化疗领域，尤其是在急性淋巴细胞白血病中发挥着重要作用。
